4th May 2020

Consilium Strategic Communications advises MaxCyte Inc. on over-subscribed £25.1 Million fundraise


London, 4 May 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is proud to have supported its client, MaxCyte Inc. (LSE: MXCT), a global clinical-stage cell-based therapies and life sciences company, on the international communication of its £25.1 million fundraise.

MaxCyte are focussed on enabling the development of new medicines and bringing highly effective advanced therapies to the patients who desperately need them. The funds from this oversubscribed financing will allow MaxCyte to accelerate and strengthen its leading position as an enabler of next generation cell based therapies as it proceeds to a dual listing on NASDAQ. The fundraise, announced on Friday 1 May 2020, was led by international specialist healthcare crossover investors Casdin Capital and Sofinnova Partners.

“We are delighted to have supported MaxCyte through this recent successful cross-over financing and look forward to continuing to work closely with Doug, Ron and the team as they carry on their exciting journey.”

Mary-Jane Elliott

Managing Partner of Consilium Strategic Communications

“We are grateful to Consilium’s terrific support and help with this transaction. We sincerely appreciate M-J and the team’s professionalism and their diligent partnership with us."

Doug Doerfler

President and Chief Executive Officer

The Consilium team representing MaxCyte Inc. on the financing news comprises Mary-Jane Elliott, Chris Welsh, Sarah Wilson and Aidina Brownlow.

MaxCyte’s announcement can be viewed in full here.




For more information, please contact:


Consilium Strategic Communications

Mary-Jane Elliott / Amber Fennell

Tel: +44(0)20 3709 5700



Follow us: @consiliumhc



About Consilium Strategic Communications

Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.


About Maxcyte

MaxCyte, the clinical-stage global cell-based therapies and life sciences company, uses its proprietary next-generation cell and gene therapies to revolutionise medical treatments and ultimately save lives. The Company's premier cell engineering enabling technology is currently being deployed by leading drug developers worldwide, including with all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted to more than 100 cell therapy programmes, with more than 70 licensed for clinical use, and the Company has now entered into nine clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT) and is headquartered in Gaithersburg , Maryland, US. For more information, visit maxcyte.com.



Back to previous page